Researcher Publications

Michael L. Gatza, PhD

Selected Publications

  1. Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM and Gatza ML. (2017). Amplification of SOX4 promotes PI3K/Akt signaling in breast cancer. Breast Cancer Research and Treatment. 162(3):439-450. PMCID:PMC5334195
  2. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang K, Lin C, McLellan M, Yan P, Davies SR, Townsend R, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich A, Fenyo D, Ellis MJ, Carr SA, NCI CPTAC. (2016). Proteogenomics connects somatic mutations to signaling in breast cancer. Nature. 534(7605):55-62. PMCID: PMC5102256
  3. Gatza ML and Carey LA (2016). Another breast cancer entity confirmed: Genomics of invasive lobular breast cancer. Journal of Clinical Oncology. 34(16):1838-9.
  4. Ciriello G*, Gatza ML*, Rhie SK, Zhang H, Bowlby R, Wilkerson MD, Kandoth C, McLellan M, Gao J, Cherniack A, Hoadley KA, The Cancer Genome Atlas Breast AWG and Network, King TA and Perou CM. (2015). Comprehensive molecular characterization of invasive lobular breast tumors. 163:506-519. PMCID: PMC4603750. *Authors contributed equally.
  5. Silva GO, He X, Parker JS, Gatza ML, Carey LA, and Perou CM (2015). Across Species DNA Copy Number Analyses Identifies Subtype-Specific Drivers of Breast Cancer Development. Breast Cancer Research and Treatment. 152(2):347-56. PMCID: PMC4491106
  6. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O’Shaughnessey JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL (2015). Activating PIK3CA mutations induce an EGFR/ERK paracrine signaling axis in basal-like breast cancer. Molecular and Cellular Proteomics. 14(7):1959-76. PMCID:PMC4587316
  7. Tian H, Liu J, Chen J, Gatza ML, Blobe GC (2015). Fibulin-3 is a Novel TGF-β pathway Inhibitor in the Breast Cancer Microenvironment. Oncogene. 34(45):5635-47. PMCID: PMC4589427
  8. Gatza ML, Silva GO, Fan C, Parker JS, and Perou CM. (2014). An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer. Nature Genetics. 46(10): 1051-1059. PMCID: PMC4300117
  9. Shats I, Gatza ML, Angus SP, Liu B, and Nevins JR. (2013). Cooperation between E2F1 and FOXO transcription factors provides a mechanism for control of E2F1-mediated transcription by survival signaling. Cancer Research. 73(19):6056-67. PMCID: PMC3815650.
  10. Gatza ML*, Kung HN*, Blackwell KL, Dewhirst MW, Marks JR, and Chi JT. (2011). Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research. 13(3):R62. PMCID: PMC3218951. (Article designated as Highly Accessed).*Authors contributed equally
  11. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford M, Datto MB, Kelley M, Mathey-Prevot B, Potti A, and Nevins JR. (2010). A pathway based classification of human breast cancer. Nat’l. Acad. Sci. 107(15):6994-6999. PMCID: PMC2872436
  12. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, and Nevins JR. (2009). Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Nat’l Acad. Sci. 106 (38):16387-16392. PMCID: PMC2752567
  13. Mori S, Chang JT, Andrecheck ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, and Nevins JR. (2009). Anchorage-independent cell growth signature identified tumors with metastatic potential. Oncogene. 28 (31): 2796-2805. PMCID: PMC3008357
  14. Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, and Nevins JR. (2009). A Genomic strategy to elucidate modules of oncogenic pathway signaling networks. Molecular Cell. 34(1): 104-114. PMCID: PMC2694616

Return to member profile


precision medicine at Rutgers Cancer Institute







Donate Now








Proud member of
Big Ten Cancer Research Consortium



Rutgers Health